Tue, February 18, 2025
Mon, February 17, 2025
[ Mon, Feb 17th ]: Forbes
Ingmar Rentzhog
Sun, February 16, 2025
Sat, February 15, 2025
Fri, February 14, 2025
Thu, February 13, 2025
Wed, February 12, 2025
Tue, February 11, 2025

Is The Alzheimer's Drug Leqembi Covered By Medicare?

  Copy link into your clipboard //business-finance.news-articles.net/content/202 .. lzheimer-s-drug-leqembi-covered-by-medicare.html
  Print publication without navigation Published in Business and Finance on by Forbes
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
  Progressive and incurable, Alzheimer's disease affects an estimated 6.7 million U.S. adults at least 65 years old, according to the Alzheimer's Association[1]. Few pharmaceuticals have any noticeable effect on Alzheimer's-related dementia and cognitive decline.

- Click to Lock Slider
Leqembi, a new Alzheimer’s treatment, has been approved by the FDA with full traditional approval, making it eligible for Medicare coverage. Previously, Medicare coverage for Alzheimer’s treatments was limited to those in clinical trials. Now, with Leqembi's approval, Medicare will cover the drug for patients with mild cognitive impairment or mild dementia due to Alzheimer’s, provided they are enrolled in Medicare Part B and their healthcare provider participates in a registry that collects data on the drug's effectiveness in real-world settings. This coverage decision marks a significant shift in policy, aiming to provide broader access to innovative treatments while still gathering necessary data on their performance outside of clinical trials. However, patients might still face out-of-pocket costs, and the coverage is contingent on the drug's registry participation.

Read the Full Forbes Article at:
[ https://www.forbes.com/advisor/health-insurance/medicare/leqembi-medicare/ ]